Data from EMC - Curated by Toby Galbraith - Last updated 21 July 2016

Indication(s)

Vildagliptin is indicated in the treatment of type 2 diabetes mellitus in adults:

As monotherapy
- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.

As dual oral therapy in combination with
- metformin, in patients with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin,
- a sulphonylurea, in patients with insufficient glycaemic control despite maximal tolerated dose of a sulphonylurea and for whom metformin is inappropriate due to contraindications or intolerance,
- a thiazolidinedione, in patients with insufficient glycaemic control and for whom the use of a thiazolidinedione is appropriate.

As triple oral therapy in combination with
- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.

Vildagliptin is also indicated for use in combination with insulin (with or without metformin) when diet and exercise plus a stable dose of insulin do not provide adequate glycaemic control.

 

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Type 2 Diabetes

View the latest epidemiology data, patient perspectives, American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) recommendations, treatment options and more

Visit Type 2 Diabetes

More information

Category Value
Orphan designation No
Type POM
Marketing authorisation holder Novartis Europharm Limited

Related Content